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Riassunto 
 
La diatomite è un biomateriale poroso naturale di origine 
sedimentaria, formata da frammenti di scheletri silicei di diatomee, 
chiamati "frustoli". Grazie alla grande disponibilità in molte aree del 
mondo, alla stabilità chimica e alla non tossicità, questo materiale 
fossile ha trovato largo impiego in molte applicazioni industriali, 
come la produzione di cibo, la purificazione dell’acqua attraverso 
l’estrazione di agenti tossici, la produzione di cosmetici e di prodotti 
farmaceutici. Tuttavia, le diatomiti non sono state ancora utilizzate in 
applicazioni biomediche. 
Nel presente studio, è stata esplorata la possibilità di utilizzare le 
diatomiti per la realizzazione di nanovettori per il delivery di molecole 
antitumorali. 
Per rimuovere le impurezze inorganiche e organiche dalle diatomiti e 
renderle un materiale sicuro per applicazioni mediche è necessaria una 
procedura di purificazione, basata sul trattamento con soluzioni calde 
di acidi forti. La polvere micrometrica è stata ridotta in nanoparticelle 
attraverso frantumazione meccanica, sonicazione e filtraggio. 
La morfologia e la composizione delle diatomiti sono state studiate 
mediante microscopia elettronica a scansione dotata di spettroscopia a 
raggi X a dispersione di energia, fotoluminescenza e misure di DLS. 
Esperimenti in vitro hanno mostrato una tossicità molto bassa dopo 
esposizione di cellule a concentrazioni di diatomiti fino a 300 µg/ml 
per 72 h. 
Le nanoparticelle sono state successivamente funzionalizzate con un 
derivato del silano (APTES) e marcate con tetrametilrodamina 
isotiocianato. Diverse concentrazioni di diatomiti marcate sono state 
incubate con le cellule tumorali e sono state osservate al microscopio 
confocale che ha mostrato un’effettiva internalizzazione cellulare e 
una distribuzione omogenea delle nanoparticelle sia nel citoplasma sia 
nel nucleo, suggerendo così la possibilità di utilizzare tali nanovettori 
per il delivery di farmaci. 
Successivamente, attraverso l’utilizzo di un linker, è stato caricato un 
siRNA fluorescente e l’analisi attraverso microscopia confocale, in 
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questo caso, ha mostrato una localizzazione esclusivamente 
citoplasmatica del vettore. Inoltre, utilizzando un siRNA specifico, è 
stato ottenuto silenziamento genico. 
I nostri studi suggeriscono che le diatomiti rappresentano un 
promettente biomateriale per lo sviluppo di nanovettori non tossici per 
il trasporto di siRNA in cellule tumorali. 
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Summary 
 
Diatomite is a natural porous biomaterial of sedimentary origin, 
formed by fragments of diatom siliceous skeletons, called “frustules”. 
Due to large availability in many areas of the world, chemical 
stability, and non-toxicity, these fossil structures have been 
widespread used in a lot of industrial applications, such as food 
production, water extracting agent, production of cosmetics and 
pharmaceutics. However, diatomite is surprisingly still rarely used in 
biomedical applications. 
In this study, the properties of diatomite nanoparticles as potential 
system for the delivery of anticancer molecules in cancer cells were 
exploited. 
A purification procedure, based on thermal treatments in strong acid 
solutions, was used to remove inorganic and organic impurities from 
diatomite and to make them a safe material for medical applications. 
The micrometric diatomite powder was reduced in nanoparticles by 
mechanical crushing, sonication, and filtering. 
Morphology and composition of diatomite were investigated by 
scanning electron microscopy equipped by energy dispersive X-ray 
spectroscopy, photoluminescence and dynamic light scattering 
measurements. In-vitro experiments show a very low toxicity on 
exposure of the cells to diatomite nanoparticle concentration up to 300 
µg/ml for 72 h. 
Diatomite nanoparticles were functionalized by 3-
aminopropyltriethoxysilane and labeled by tetramethylrhodamine 
isothiocyanate. Different concentrations of chemically modified 
nanoparticles were incubated with cancer cells and confocal 
microscopy was performed. Imaging analysis showed an efficient 
cellular uptake and homogeneous distribution of nanoparticles in 
cytoplasm and nucleus, thus suggesting their potentiality as 
nanocarriers for drug delivery. 
Subsequently, siRNA bioconjugation were performed and confocal 
microscopy imaging on cancer cells incubated with siRNA-
conjugated nanoparticles demonstrated a cytoplasmatic localization of 
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vectors. Gene silencing by delivered siRNA was also demonstrated. 
Our studies endorse diatomite nanoparticles as non-toxic nanocarriers 
for siRNA transport in cancer cells. siRNA-diatomite nanoconjugate 
may be well suited for delivery of therapeutic to cancer cells.  
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1. Introduction 
 
1.1 Drug delivery 
The drug delivery is a research field that has captured the interest and 
curiosity of researchers because delivering a medicine to its site of 
therapeutic action is one of the main limitations of pharmaceutical and 
biotechnology industries [1] The drug delivery can be defined as a 
releasing process of a bioactive agent at a specific rate and at a 
specific site. The targeted drug delivery can be useful to exploit 
thousands of new therapeutics that are limited by a safe and effective 
drug-delivery system [1,2]. The discovery of new drugs classes is 
crucial to set up specific drug-delivery methods to activate these new 
advances into clinical effectiveness. The conventional drugs are 
limited by their poor solubility, non specific delivery, high toxicity, 
high dosage, in vivo degradation and short circulating half-lives, but 
at present, the field of drug delivery is developing rapidly to reduce 
the drugs' ever-increasing problems [1]. The drug delivery field has 
also attracted the attention of the pharmaceutical industry because it 
offers new tools to develop current drug markets. Targeted drug-
delivery systems can transport drugs more effectively then the 
conventional system and it can extend the provide product 
differentiation, product life cycle, and reduce patient healthcare costs 
[3]. In addition, these systems would improve the pharmacokinetics 
and the short half-lives of degradable peptides and proteins in vivo 
[4,5]. Therefore, one of the most important areas of drug research is 
the development of techniques that could selectively deliver drugs to 
the pathological sites [6]. NPs can be correctly envisioned as the 
future of drug-delivery technology as they have the potential to 
become useful therapeutic and diagnostic tools in the near future [7]. 
 
1.2 Nanotechnology as a solution for drug delivery 
Nanotechnology is the creation and handling of materials, devices and 
systems through the control of matter on the nanometer-length scale.  
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Due to the small size and dimensional similarities to biomolecules, 
nanomaterials exhibit a far greater intracellular uptake as compared 
with micro sized particles, making them excellent candidates for 
targeted drug delivery [8]. More importantly, nanomaterials also offer 
attractive possibilities to circumvent the vascular barriers and 
biological defense systems of the body. For instance, micro sized 
particles are easily taken up by the macrophages widely distributed 
throughout the body and this leads to rapid clearance of the 
microparticles from the bloodstream by the reticulo endothelial 
defence mechanism [9,10]. Considering that extremely tiny 
capillaries, of about 2.3 micrometers in diameter, have been observed 
[11], well designed nanomaterials of controlled size range (sub-200 
nm) can increase the opportunities to deliver drug payloads precisely 
to the diseases. 
Furthermore, nanomaterials can carry a large number of imaging 
and/or therapeutic agents owing to their enormous surface area 
relative to their total volume. For example, a polymeric nanoparticle 
having an average diameter of 70 nm is able to contain approximately 
2,000 drug molecules [12], while a polymer-drug conjugate carries 
only nine drug molecules per molecule [13]. In addition they offer a 
possibility of surface modification with multiple targeting moieties 
(such as small molecules, peptides, or antibodies) for effective disease 
targeting. Recent researches have proven that the multiple attachment 
of a targeting ligand significantly enhances the intracellular uptake of 
the ligand-functionalized nanovehicles in the target cancer cells via 
the multivalent binding to the cell-surface receptors [14,15]. Hence a 
nanocarrier system possessing a number of targeting ligands can be 
effectively exploited for targeting to the tumor tissues with a specific 
uptake. 
Nanotechnology focuses on formulating therapeutic agents in 
biocompatible nanocarriers, including polymeric NPs, ceramic NPs, 
magnetic NPs, polymeric micelles and dendrimers.  
A successful nanocarrier should ideally meet the following 
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requirements: (1) formulation with biocompatible and/or 
biodegradable materials, (2) high drug loading capacity, (3) site- 
specific delivery mechanism to avoid normal cells and tissues, (4) 
zero or negligible premature drug release, and (5) controlled release 
mechanism to provide an effective dose to the target site [16]. A 
natural material that possesses those features is represented by 
diatomite. 
 
1.3 Diatomite 
Diatomaceous earth, also known as diatomite, is a fossil material of 
sedimentary origin, formed over centuries by siliceous skeleton 
(called “frustule”) of aquatic unicellular microalgae, the diatoms, 
deposited on bottom of lakes or present in marine environments. 
Diatomite morphology can be very complex due to the presence of 
diatom frustules with different sizes (ranging from 2 µm to 2 mm) and 
shapes. The structure is highly porous and characterized by a large 
specific surface area up to 200 m2/g [17]. The main constituent of 
diatomite is amorphous silica (70% - 90%), although it can contain 
impurities such as organic components and metallic oxides (MgO, 
Al2O3, Fe2O3) coming from environment [17,18]. Different strategies, 
including calcination processes and hot acid treatments, have been 
developed to remove impurities from frustules [19,20]. Due to large 
availability in many areas of the world, chemical stability, and non-
toxicity, this fossil material has been widespread used in lot of 
industrial applications, such as food production, water extracting 
agent, production of cosmetics and pharmaceutics [21-24]. 
Recently, diatom frustules have been exploited as an innovative 
platform in several biotechnological applications [25,26]. In fact, the 
silica surface of diatoms, covered by reactive silanol (Si-OH) groups, 
can be modified with functional reactive groups (-NH2, -COOH, -SH, 
-CHO) for the immobilization of biomolecular probes (DNA, 
antibodies, enzymes) [27]. Moreover, the porous structure allows the 
binding of a large amount of bioprobe molecules with respect to a flat 
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surface, thus increasing sensitivity of biosensing. In recent works, we 
reported the chemical modification of marine diatom frustules with 
antibody as highly selective bioprobe. The antibody–antigen 
molecular recognition was investigated by means of 
photoluminescence and fluorescence microscopy [28,29]. 
Although diatomite, differently from diatom frustules, is a cheaper 
material produced in tons by mining industry, it is surprisingly still 
scarcely used in biomedical applications. Recent pioneering papers 
demonstrated the use of diatomite as microcapsules for oral drug 
delivery [30,31].  
 
 
 
Figure 1 TEM image of diatomite nanoparticles 
 
1.4 Scientific hypothesis and aim of the work 
In this work, porous diatomite nanocarriers, with an average diameter 
less than 450 nm, were bioconjugated with small interfering 
ribonucleic acid (siRNA) in order to test their drug delivery 
capability. As a matter of fact, siRNA is a powerful approach for 
silencing genes associated with a variety of pathologic conditions but 
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its systemic delivery is inefficient due to the difficulty to penetrate the 
cell membrane [32,33]; its conjugation to nanovectors (including 
liposomes, gold and magnetic nanoparticles, quantum dots) is one of 
the possible strategies developed to overcome this challenging 
problem [34,35]. In particular, we have investigated diatomite 
nanoparticles cytotoxicity and examined their ability to transport 
siRNA inside cancer cells and to silence gene expression. The results, 
compared with those reported in literature on standard systems 
[36,37], encourage the use of diatomite nanoparticles as drug carriers. 
Materials and Methods 
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2. Materials and Methods  
 
2.1 Materials 
Calcined diatomite was obtained by DEREF Spa (Italy); 3-(4,5- 
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), (3- 
aminopropyl)triethoxysilane (APTES), Tris(2carboxyethyl)phosphine 
hydrochloride (TCEP), tetramethylrhodamine isothiocyanate 
(TRITC), dimethyl sulfoxide (DMSO) and H2SO4 were purchased 
from Sigma-Aldrich (MO, USA). Phosphate buffered saline (PBS) 
was purchased from GIBCO (CA, USA). N-(γ-Maleimidobutyryloxy) 
sulfosuc-cinimide ester (Sulfo-GMBS), on target plus smart pool 
human GAPDH (siRNA GAPDH), on target plus control pool non-
targeting pool (siRNA scramble, SCR) and siGLO RISC-Free control 
siRNA (siGLO RNAi), chemically modified to impair processing and 
uptake by RISC, were from Thermo Scientific (MMedical, Milan, 
Italy). Synthesis of poly D-Arg peptide (sequence RRRRRRRRC) and 
non-polar homopeptide was performed by Proteogenix (FR). HCl was 
purchased from Romil (UK). Absolute ethanol, Tris-
(hydroxymethyl)aminomethane, NaCl and H2O2 were purchased from 
Carlo Erba (IT). Rabbit anti-GAPDH polyclonal antibody was 
purchased from Cell Signaling Technology Inc. (MA, USA). Rabbit 
anti-β-tubulin polyclonal antibody and goat anti-rabbit 
immunoglobulin conjugated to horseradish peroxidase were from 
Santa Cruz Biotechnology (CA, USA). 
 
2.2 Diatomite purification treatment 
5 g of diatomite powder was dissolved in 250 ml of absolute ethanol 
and sonicated for 5 h in order to break up macroscopic aggregates. 
The dispersion was filtered through a nylon net filter with pore size of 
40 µm (Millipore) and then filtered with pore size of 0.45 µm 
(Millipore, Billerica, MA, USA). Dispersion of diatomite nano- 
particles was centrifuged at 15,000 ×g for 30 min, and the supernatant 
was removed. 
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Diatomite nanopowder was purified to remove organic and inorganic 
contaminants [17,19]. To this aim, diatomite dispersion was 
centrifuged and the pellet was suspended in piranha solution (2 M 
H2SO4, 10% H2O2) for 30 min at 80 °C. Dispersion was then 
centrifuged for 30 min at 15,000 ×g and supernatant was removed. 
Diatomite was washed twice with deionized water. Subsequently, 5.0 
M HCl solution was added to diatomite and incubated overnight at 80 
°C. After HCl incubation, diatomite dispersion was centrifuged for 30 
min and supernatant was removed. Pellet was washed twice with 
deionized water that removed excess of HCl.  
 
2.3 Characterization of nanoparticles size 
Scanning electron microscopy (SEM) equipped with energy 
dispersive X-ray spectroscopy (EDS) (Fei, Quanta 200 FEG) was 
used to investigate nanoparticles morphology. Briefly, for SEM 
characterization diatomite samples were deposited on crystalline 
silicon substrates mounted on a double-faced conductive adhesive 
tape. Images were acquired at 5-kV accelerating voltage and 30-µm 
wide aperture.  
The size and zeta-potential measurements of purified diatomite 
nanoparticles dispersed in water (pH = 7) were performed by dynamic 
light scattering (DLS) using a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, UK) equipped with a He-Ne laser (633 nm, 
fixed scattering angle of 173°, 25°C). 
 
2.4 Steady-state photoluminescence 
Steady-state photoluminescence (PL) spectra were excited by a 
continuous wave He–Cd laser at 325 nm (KIMMON Laser System). 
PL was collected at normal incidence to the surface of samples 
through a fiber, dispersed in a spectrometer (Princeton Instruments, 
SpectraPro 300i), and detected using a Peltier cooled charge coupled 
device (CCD) camera (PIXIS 100F). A long pass filter with a nominal 
Materials and Methods 
 8 
cut-on wavelength of 365 nm was used to remove the laser line at 
monochromator inlet. 
 
2.5 Cell culture 
The human lung epidermoid carcinoma cell line (H1355) was 
obtained from the American Type Tissue Collection (Rockville, MD, 
USA). The cell line were grown in RPMI 1640 (GIBCO) medium 
supplemented with 10% heat inactivated FBS (GIBCO), 100 U/ml 
penicillin, 100 mg/ml streptomycin, and 1% L-glutamine at 37 °C in a 
5% CO2 atmosphere.  
 
2.6 Cell viability assay 
Cells were seeded into 96-well microtiter plates (BD Falcon, USA) at 
the density of 30 × 103 cells/well and allowed to attach for 24 h. After 
incubation, the medium was removed and a fresh cell growth medium 
was added (100 µl/well). 
Diatomite nanoparticles at concentrations of 0, 20, 50, 100, 200, and 
300 µg/ml were added into different wells in triplicate and incubated 
with cells for 24, 48, and 72 h. After treatment, the cell viability was 
assessed using MTT assay. 10 µl of a 5 mg/ml MTT solution in RPMI 
1640 no phenol red (Sigma) was added to each well. Plates were then 
incubated under cell culture conditions for 3 h. Subsequently, 100 µl 
of MTT solvent (HCl 0.1 N in isopropanol) was added to each well 
and incubated for 1 h at room temperature with stirring to dissolve the 
formazan crystals. Absorbance of each sample was detected by 
Microplate Reader 680 (Biorad) at 570 nm. 
 
2.7 Diatomite chemical functionalization 
After purification treatments, diatomite surface was amino-modified 
by incubation with a 5% (v/v) (3-Aminopropyl)triethoxysilane 
(APTES) solution in absolute ethanol, following typical silanization 
processes [38,39]. Briefly, the reaction was performed for 1 h at room 
temperature with stirring in dark condition. Dispersion was then 
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centrifuged for 30 min at 15,000 ×g and supernatant was removed. 
The functionalized diatomite was washed twice with absolute ethanol; 
the collected pellet was incubated for 10 min at 100 °C (curing 
process). After incubation, the sample was resuspended and washed 
twice with absolute ethanol and then twice with PBS 1× pH 7.4. 
 
2.8 Fourier-transform infrared spectroscopy 
Chemical composition of APTES-functionalized diatomite 
nanoparticles was analyzed by Fourier-transform infrared (FTIR) 
spectroscopy. Spectra were recorded by a Thermo-Nicholet NEXUS 
Continuum XL (Thermo Scientific, Waltham, MA, USA) equipped 
with a micro- scope, at 2 cm−1 resolution on samples deposited on 
silicon chips (p-type, 0.003 ohm cm resistivity, <100 > oriented, 500-
µm tick) of about 1 cm × 1 cm. 
 
2.9 Nanopowder diatomite labeling 
Diatomite labeling procedure was based on the use of an 
aminoreactive molecule, tetramethylrhodamine isothiocyanate. 
TRITC powder was solved in dimethyl sulfoxide (DMSO) and 
incubated with diatomite nanopowder in the presence of NaHCO3 0.1 
M pH 8.7 with stirring for 1 h at room temperature in dark conditions. 
Subsequently, the sample was washed with distilled water to remove 
TRITC excess, until no fluorescence was revealed in the supernatant 
when analyzed by fluorescence microscopy. Labeled diatomite 
nanoparticles will be indicated as DNPs*. 
 
2.10 Confocal microscopy 
H1355 cell line (20 × 103 cells/coverslip) was plated on 10-mm glass 
coverslips placed on the bottom of 24-well plate, allowed to attach for 
24 h under normal cell culture conditions, and then incubated with 
increasing DNPs* concentration (5, 10, 15 µg/mL) for 24 h. As 
negative control, the last supernatant obtained from nanoparticles 
labeling procedure was added to the cells. Cell nuclei and membranes 
Materials and Methods 
 10 
were then stained with Hoechst 33342 (Invitrogen, Carlslab, CA, 
USA) and WGA-Alexa Fluor 488, respectively. 
Images were acquired at 63× magnification on a LSM710 confocal 
fluorescence microscope (Carl Zeiss Inc., Peabody, MA, USA) with 
the appropriate filters.  
 
2.11 Cross-linker chemistry 
APTES-functionalized diatomite was incubated with 20 mM Sulfo-
GMBS in PBS for 1 h with stirring at room temperature. 
Subsequently, the sample was washed twice with PBS 1× to remove 
Sulfo-GMBS excess. 
 
2.12 Peptide/siRNA complex 
The relative concentrations of peptide and siRNA required to form a 
stable complex have been investigated by incubating 50 pmol of 
siRNA with different amounts of arginine peptide for 2 h at room 
temperature in PBS, with a peptide/siRNA charge ratio ranging from 
0 to 20. 
The ratio between peptide (NH3+ ) and siRNA (PO4− ) was defined as 
the nitrogen/phosphate (N/P) ratio. Peptide/siRNA complexes were 
analyzed by electrophoretic mobility shift assay (EMSA) on a 20% 
polyacrylamide gel in TAE (40 mM Tris acetate/2 mM EDTA) buffer 
at 100 V for 70 min, followed by staining with ethidium bromide 
(EtBr) for 20 min. 
In addition, the stability of siRNA to nuclease was evaluated in the 
absence and presence of poly-Arg peptide. The samples were 
incubated in PBS for 30 min in the presence of human pancreatic 
ribonuclease, gently provided by Prof. De Lorenzo, that is able to 
degrade double-strand RNA [40]. Samples were then analyzed by 
EMSA. 
Finally, in order to assess the optimal peptide concentration, Sulfo- 
GMBS modified diatomite was incubated with increasing concentra- 
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tions (75, 150, 300 µM) of labeled peptide and fluorescence intensity 
was analyzed. 
 
2.13 siRNA loading 
0.5 mg of sulfo-GMBS modified diatomite was incubated with the 
complex formed by peptide and siRNA for 1 h at room temperature in 
dark condition. 
Complex was obtained by mixing 150 µM peptide with 7.5 µM 
siRNA (molar ratio 20:1) in the presence of a 10-fold molar excess 
with respect to the peptide concentration of a reducing agent, Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), in 1× PBS at room 
temperature for 2 h in dark condition [41,42]. Subsequently, diatomite 
suspension was centrifuged and the pellet was collected and washed 
twice with PBS 1×. 
The siRNA loaded was about 0.7 pmol per 1.0 µg of diatomite, as 
determined by UV reading at 260 nm. 
 
2.14 Fluorescence microscopy 
Fluorescence of diatomite modified with Dy547 labeled siRNA 
(siRNA*) was investigated by means of Leica Z16 APO fluorescence 
macroscope equipped with a camera Leica DFC300, using an optics 
constituted by a 515–560 nm band-pass excitation filter, a 580 nm 
dichromatic mirror, and a 590 nm suppression filter. Analysis was 
performed on diatomite samples deposited on silicon substrates. Fluo- 
rescence values reported in the work are the average of three different 
measurements. 
 
2.15 siRNA release profile 
The siRNA release profile was performed by suspending siRNA* 
modified diatomite in 20 mM TrisHCl pH 7.5 and 20 mM NaCl at 
room temperature and then monitoring the fluorescence intensity in 
the supernatant and in diatomite at different time points. Images were 
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acquired on an Axiovert 40 CFL Zeiss and fluorescence intensity was 
analyzed by using ImageJ software 1.41o (http://imagej.nih.gov/ij/). 
 
2.16 Confocal microscopy of nanoparticles internalization 
Cells (50 × 103/coverslip) were plated on 10 mm glass coverslips 
placed on the bottom of 24-well plate, allowed to attach for 24 h 
under normal cell culture conditions and then incubated with siRNA* 
modified diatomite nanoparticles (300 µg/ml) for 18 h. Cells were 
washed with PBS, fixed in 4% formaldehyde for 30 min, washed 3 
times with PBS and stained with membrane stain WGA-Alexa Fluor 
488 Conjugate (Invitrogen, Carlslab, CA) according to the 
manufacturer's instructions. Cell nuclei were then stained with 
Hoechst 33342 (Invitrogen, Carlslab, CA). 
Images were acquired at 63× magnification on a LSM710 confocal 
fluorescence microscope (Carl Zeiss Inc., Peabody, MA) with the 
appropriate filters. 
 
2.17 Gene knockdown 
Cells (150 × 103/well) were seeded into six-well plates 24 h before 
incubation with GAPDH and non-targeting (SCR) siRNA modified 
diatomite nanoparticles (100 pmol siRNA/140 µg diatomite) in 
RPMI1640. After 72 h of incubation, the cells were used for Western 
blot analysis. 
Transfection with 100 pmol GAPDH and SCR siRNAs by using 
Lipofectamine 2000 (LF2000) according to the manufacturer's 
instructions (Invitrogen) was used as comparison. 
H1355 cells were scraped, washed twice in cold 1× PBS, and 
resuspended in 20–40 µl of lysis buffer (50 mM Tris HCl pH 7.4, 1% 
NP40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mg/ml 
aprotinin, leupeptin, pepstatin, 1 mM Na3VO4, 1 mM NaF) for 30 min 
on ice and centrifuged at 14,000 ×g for 20 min at 4 °C. 
Protein concentration was determined by a modified Bradford 
method, using the Bio-Rad protein assay and compared with BSA 
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standard curve. Cytosolic proteins (10 µg) were separated by SDS-
PAGE, electrotransferred to nitrocellulose and reacted with the 
different antibodies. Blots were then developed using enhanced 
chemiluminescence detection reagents (SuperSignal West Pico, 
Pierce) and exposed to X-ray film. All films were scanned for 
densitometric analysis by using ImageJ 1.41o software 
(http://imagej.nih.gov/ij/). 
Results 
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3. Results 
 
3.1 Characterization of diatomite nanoparticles 
Natural diatomite are generally contaminated by organic residues and
inorganic oxides [17,19]. Biomedical applications require strong
purification treatments of vectors in order to obtain pure silica as safe
and biocompatible material. Fig. 2 shows SEM images of diatomite
deposited on silicon support, before (A) and after (B) purification
treatments in strong hot acids. 
 
 
 
  
 
Figure 2 SEM images of diatomite deposited on silicon before (A) and after (B)
purification treatments; corresponding EDS graphs (C–D). 
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Before purifications, the features of diatomite were completely 
masked by the presence of many impurities on their surface; EDS 
spectra showed changes in chemical composition of the samples: after 
cleaning treatments, the intensities of peaks corresponding to calcium, 
iron and aluminum decreased, whereas the silica peak increased (Fig. 
2C and D). Detailed chemical composition of diatomite before and 
after purification is summarized in Table 1. 
 
Table 1 Chemical composition of frustules before and after purification treatments. 
 
 
The purification procedures have also been investigated by 
photoluminescence analysis. 
Under UV excitation (325 nm), diatomite samples showed a blue 
photoluminescence, clearly visible by naked eye. Even if the origin of 
this emission is not completely clear, it is commonly believed that it is 
mainly originated from surface defects including OH− groups and 
oxygen vacancies [43]. Laser pumping generates excited electrons 
whose radiative decay produces photoluminescence emission. 
Fig. 3 shows the comparison between photoluminescence spectra of 
diatomite before (A) and after (B) treatments. The untreated sample 
was characterized by a weak signal with three main features peaked at 
390 nm (3.18 eV), 460 nm (2.7 eV), and 500 nm (2.48 eV). 
After treatment, the peak at 390 nm became weaker, another peak at 
423 nm (2.93 eV) appeared, while the feature at 500 nm shifted to 490 
nm (2.53 eV). These modifications were due to the removal of 
metallic impurities from the diatomite surface. The absence of 
impurities significantly modified the photoluminescence signal 
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changing reactions of energy transfer by surface radiative 
recombination.  
 
 
 
Figure 3 Photoluminescence spectra of untreated diatomite (A) and diatomite after 
piranha and HCl treatments (B). 
 
Size and surface charge of purified diatomite nanoparticles dispersed 
in water (pH = 7) were determined by DLS. The average size and 
zeta-potential of nanoparticles were 220 ± 90 nm and −19 ± 5 mV, 
Results 
 17 
respectively (Figure 4). The negative value of zeta-potential was due 
to the presence of silanol groups on nanoparticles surface after 
treatment in Piranha solution. 
 
 
 
Figure 4 Size (upper graph) and zeta potential (lower graph) distributions of 
diatomite nanoparticles in water (pH = 7) 
 
3.2 Biocompatibility  
A critical issue for biomedical applications of new nanocarriers for 
drug delivery is the evaluation of their potential toxicity and 
biocompatibility [30,36,37]. 
In vitro cytotoxicity of DNPs was evaluated by MTT assay, a method 
based on the reduction of 3-(4,5-dimethythiazol- 2-yl)-2,5-diphenyl 
tetrazolium bromide by cellular oxidoreductases of viable cells, that 
yield a crystalline blue formazan product. H1355 cells were incubated 
with different concentrations of diatomite nanoparticles for 24, 48 and 
72 h. The results obtained are reported in Fig. 5. 
Results 
 18 
The exposure of H1355 cells to increasing nanoparticle concentra- 
tions (20 µg/ml, 100 µg/ml, 200 µg/ml and 300 µg/ml) induced very 
low toxicity being the average viability of the cells slightly lower than 
100%. This result also demonstrated that the irregular shape of 
diatomite nanoparticles did not influence cell growth and morphology. 
In conclusion, the MTT assay showed that H1355 cell viability was 
not affected even after 72 h of exposure to diatomite nanopowder 
concentration up to 300 µg/ml, thus confirming their usability as 
nanovectors in nanomedicine for therapeutic applications [44,45]. 
 
 
 
Figure 5 Cytotoxicity assessment of diatomite nanoparticles using MTT assay. Cell 
viability of H1355 cells treated with 20, 100, 200 and 300 µg/ml of nanoparticles for 
24, 48 and 72 h at 37 °C. Data represent the mean ± s.d. (n = 3). Cell viability was 
expressed as the percentage of viable cells compared with cells cultured without 
nanoparticles as control (100%). 
 
3.3 Silanization  
Hot acid-treated nanoparticles were functionalized with APTES 
solution to allow an aminosilane coating on their surface. The 
functionalization procedure is fully sketched in scheme 1.  
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Scheme 1 Simplified functionalization scheme of diatomite nanoparticles with 
labeled siRNA (siRNA*). 
 
Silanol groups on diatomite surface were formed by hydroxylation 
using aqueous sulfuric acid. APTES in organic anhydrous solvent 
reacted with silanol groups on the activated surface producing 
siloxane linkages. 
Diatomite silanization was evaluated by FTIR spectroscopy. The 
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comparison between FTIR spectra of bare nanoparticles (upper graph) 
and APTES-functionalized powders (lower graph) is reported in 
Figure 6. The peak of Si-O-Si bond at 1,100 cm−1, characteristic of 
diatomite frustules, is well evident in both spectra. Before APTES 
functionalization, it is also detected the peak at 3,700 to 3,200 cm−1 
corresponding to Si-OH group. The spectrum of functionalized 
sample showed the silane characteristic peaks in the range between 
1,800 and 1,300 cm−1 (see the inset of Figure 4); in particular, the 
peak at 1,655, corresponding to imine group and the peak at 1,440 
cm−1, corresponding to asymmetric deformation mode of the CH3 
group, were observed, according to results already reported [46,47]. 
FTIR characterization clearly demonstrated the silanization of silica 
nanoparticles. 
 
 
Figure 6 FTIR spectra of nanoparticles before (upper graph) and after (lower graph) 
APTES functionalization 
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3.4 Confocal microscopy analysis and DNPs* internalization 
Nanoparticle cell uptake was studied by using DNPs* and confocal 
microscopy analysis. H1355 cells have been incubated with DNPs* at 
increasing concentrations (5, 10, 15 µg/mL) for 24 h. Figure 7 shows 
representative confocal microscopy images of cells treated with 
DNPs* compared to untreated cells as control. Cell nuclei were 
stained with Hoechst 33342 (blue), cell membranes were stained with 
WGA-Alexa Fluor 488 (green), and DNPs were labeled with TRITC 
(red). Images show an increase of fluorescence intensity at increasing 
DNPs* concentration and a homogeneous particles distribution in the 
cytoplasm and into nuclei. 
 
 
Figure 7 Confocal microscopy image of H1355 cells incubated with different 
concentrations of DNPs*; scale bar corresponds to 20 µm.  
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To prove the internalization of the carriers in the cells, images at 
different focal depth were recorded. Figure 8 shows that going from 
upper cell surface to the focus inside the cells, an increase of red 
diatomite fluorescence can be observed thus indicating the uptake of 
DNPs* by H1355 cells. 
 
Figure 8 Confocal microscopy image with different focal depth of H1355 cells 
incubated with 10 µg/mL of DNPs*. 
 
3.5 Study of siRNA loading into diatomite nanoparticles and in vitro 
release 
siRNA*, complexed with a poly D-Arg peptide, was loaded onto 
diatomite nanoparticles following the functionalization procedure 
sketched in Scheme 1. Briefly, APTES-functionalized diatomite reacts 
with sulfo-GMBS, a heterobifunctional cross linker reactive to amino 
groups at one end and to sulfhydryl groups at the other. The NHS 
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ester reacts with the amino-modified diatomite surface as a 
nucleophile with release of the sulfo-NHS leaving group forming an 
amide bond. Peptide/siRNA* complex (molar ratio 20:1) was 
immobilized on the diatomite surface through the thioether bond 
between the sulfhydryl group of peptide cysteine residue and C-C 
bond of the maleimide ring of Sulfo-GMBS. A nonpolar homopeptide 
was used as control for aspecific interactions with siRNA. 
The molar ratio peptide/siRNA* used in the functionalization proce-
dure has been established by a gel shift assay, highlighting the 
complex electrostatic interaction as function of the positive peptide 
(NH3+)/negative RNA (PO4−) charge ratios. siRNA (50 pmol) was 
mixed with arginine peptides at various N/P ratios (0–20). The results 
showed that the electrophoretic migration of RNA was retarded with 
an increasing ratio of peptide/RNA (Fig. 9A). 
 
 
 
Figure 9 (A) Poly D-Arg peptide (N) and siRNA (P) were incubated at different 
molar ratios (range 0–20, as indicated above each lane) and the formed complex was 
analyzed by gel shift. (B) Effect of HP-RNase on siRNA degradation; siRNA alone 
(lane a), siRNA incubated with HP-RNase in absence (lane b) or in the presence 
(lane c) of poly D-Arg peptide. 
 
The intensity of the siRNA band decreased as the N/P ratio increased. 
No siRNA band was observed at the N/P ratio of 20. This absence of 
migration was probably due to the complete neutralization of nucleic 
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acid charge by the arginine peptide and/or formation of a large 
complex between the arginine and siRNA. These results strongly 
suggest that an arginine peptide made of 8 residues could be sufficient 
to form a complex with a siRNA. 
In addition, since the first biological barrier of siRNA delivery is its 
susceptibility to nucleases that causes its rapid degradation, the 
capability of the peptide/siRNA complex to protect siRNA from 
nuclease degradation was investigated. For this purpose, human 
pancreatic ribonuclease (HP-RNase), able to degrade double-strand 
RNA, was used [40]. As shown in Fig. 9B, siRNA was rapidly 
degraded by HP-RNase (lane b), while, when preincubated with 
peptide before adding RNase, no significant degradation was ob- 
served (lane c). Our data confirmed that a poly D-Arg peptide 
strongly interacts with siRNA forming a highly stable complex as 
previously reported [40,41]. Furthermore, the formation of the 
peptide/siRNA complex improved the siRNA stability protecting it 
from nuclease degradation [48]. 
Diatomite functionalization was evaluated by means of fluorescence 
microscopy and photoluminescence analysis.  
The images reported in fig. 10A shows diatomite incubated with poly 
D-Arg peptide/ siRNA* (left image) and control peptide/siRNA* 
(right image). High red fluorescence (average intensity = 27 ± 2) was 
well evident only using poly D-Arg peptide/siRNA*; conversely, 
diatomite incubated with control peptide/siRNA* appeared darker 
(average intensity = 9 ± 1). The result was confirmed by PL 
measurements. PL spectra of diatomite functionalized with poly D-
Arg peptide/siRNA* and control peptide/siRNA* are compared in 
Fig. 10B. Only the sample functionalized with specific peptide was 
characterized by a strong PL peak at 575 nm due to the presence of 
labeled nucleic acid. 
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Figure 10 (A) Fluorescence microscopy images of diatomite modified with Poly D-
Arg peptide/siRNA* (left image) and with a control peptide/siRNA* (right image); 
(B) corresponding photoluminescence spectra. 
 
The capability of loaded diatomite to release in solution siRNA* was 
also investigated by measuring the fluorescence intensity of both 
supernatant and diatomite as function of time (Fig. 11). siRNA was 
released into supernatant in two phases: an initial phase of 12 h (burst 
release), followed by slow and sustained release phase over 48–72 h. 
The fluorescence profile of diatomite showed an opposite trend. 
The slow siRNA release observed was probably due to the 
progressive weakening of the electrostatic interactions between 
peptide and nucleic acid. 
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Figure 11 Fluorescent labeled siRNA bound to DNPs (DNPs–siRNA*) was 
incubated in 20 mM Tris–HCl and 20 mM NaCl, pH 7.5 at 37 °C and at time 
intervals the fluorescence intensity was measured in the sample supernatant (●) and 
diatomite (■). 
 
H1355 cells were incubated with siRNA* modified diatomite 
nanoparticles (DNPs–siRNA*) to evaluate the siRNA uptake and 
cellular internalization. Fig. 12 shows a representative confocal 
microscopy image of cells treated with DNPs–siRNA* compared to 
untreated cells as control. 
Fluorescence images show cell nuclei stained with Hoechst 33342 
(blue) and cell membranes with WGA-Alexa Fluor 488 (green). 
Confocal microscopy analysis was performed after treatment with 
DNPs–siRNA* for 24 h. 
In Fig. 12 the presence of siRNA (labeled with Dy547, red) into the 
H1355 cells treated with DNPs–siRNA* is evident. Merge image 
reveals that siRNA molecules are localized in the cytoplasm of cells 
and no signals were observed inside the nucleus. Red fluorescence 
(siRNA*) was found as both spots and diffuse signal [42,49-51]. 
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The efficiency of DNPs–siRNA* internalization was quantified by 
fluorescence microscopy: counting the number of red fluorescent cells 
and the total number of cells (determined in bright field), a ratio of 
about 75% was calculated. 
 
 
Figure 12 Confocal microscopy on cells treated with siRNA* modified diatomite 
nanovectors (first line) and untreated cells as control (second line). Cell nuclei and 
membranes were stained with Hoechst 33342 and WGA-Alexa Fluor 488, 
respectively. siRNA was labeled with Dy547. Scale bar corresponds to 20 µm. 
 
3.6 Gene silencing 
Finally, the ability of the DNPs–siRNA complexes to silence in 
H1355 cells targeted mRNA was investigated by Western blot 
analysis. In particular, a siRNA against glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and a scramble siRNA as control were 
used. Moreover, to compare the efficiency of the DNPs–siRNA 
delivery system with that of other system, the commercially available 
Lipofectamine 2000 transfection reagent was used. The obtained 
results are reported in Fig. 13.  
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Figure 13 (A) Immunoblotting analysis of GAPDH (upper gel) and of β-tubulin 
(lower gel) of protein expression in DNPs–siRNA treated cells. Lanes: 1) control 
cells; 2) DNPs–GAPDH–siRNA; 3) DNPs–SCR–siRNA. (B) Densitometric 
intensity band ratio of GAPDH and β-tubulin used as internal control. The 
intensities of the bands were expressed in arbitrary units. (C) Immunoblotting 
analysis of GAPDH (upper gel) and of β-tubulin (lower gel) protein expression in 
lipofectamine-siRNA transfected cells. Lanes: 1) control cells; 2) GAPDH–siRNA; 
and 3) SCR–siRNA. (D) Densitometric intensity band ratio of GAPDH and β-
tubulin used as internal control. The intensities of bands were expressed in arbitrary 
units. Each measurement and Western blot was carried out in triplicate. Error bars 
indicate the maximum deviation from the mean value of two independent 
experiments 
 
Compared to untreated cells, GAPDH protein expression level after 
incubation of the cells with DNPs–siRNA complexes at 37 °C for 48 
h was reduced (Panel A, upper gel) of about 22% (lane 2) as evaluated 
from the densitometric intensity of the bands (Panel B). Cells 
incubated with DNPs–SCR–siRNA (lane 3) showed instead almost 
identical protein expression level as control (lane 1), thus 
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demonstrating the selective inhibition by siRNA. Panels C and D 
report the expression level and the densitometric analysis, 
respectively, of cells transfected with lipofectamine. In this case, 
GAPDH protein expression level (lane 2) was down-regulated of 
about 20%. 
Even if the delivery efficiency of DNPs and lipofectamine 2000 is 
similar, the use of diatomite as nanocarrier is more suitable for 
medical applications since it allows: slow release of the loaded drug, 
loading with one or more different molecules (e.g. siRNA + drug), 
biocompatibility and selective targeted functionalization to improve 
the delivery of anti-tumoral molecules to specific cell population. 
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4. Conclusions 
 
Nanocarriers have emerged as an important tool for clinical 
applications and tumor-specific delivery of siRNA has great potential 
for successful targeted cancer therapy. In this work, a procedure to 
make diatomite, a natural porous biomaterial of sedimentary origin, 
suitable for the delivery of anticancer molecules into cells was settled. 
Purified diatomite nanoparticles morphology and surface chemical 
modifications were investigated by scanning electron microscopy 
equipped by energy dispersive X-ray spectroscopy, 
photoluminescence, dynamic light scattering measurements and 
Fourier transform IR spectroscopy. In-vitro toxicity studies 
highlighted the non-toxic nature of nanoparticles. An effective uptake 
of the engineered nanovectors into human epidermoid carcinoma 
cells, localized both in cytoplasm and nucleous, was observed after 
functionalization with APTES and labeling with tetra-
methylrhodamine isothiocyanate. Subsequently, when a labeled small 
interfering RNA was loaded on the nanoparticles, confocal 
microscopy analysis revealed an efficient nanoparticle uptake 
exclusively into cytoplasm. Finally, NPs loaded with siRNA were 
able to induce gene silencing at a level comparable with that of 
common transfectans. 
These findings demonstrate that diatomite nanoparticles, with their 
versatile structure and porosity, could represent a promising tool for 
the delivery of anticancer molecules such as siRNA, probably miRNA 
and drugs, inside cancer cells. Nevertheless, to create DNPs suitable 
for clinical applications, without undesirable side effects, better and 
more extensive in vivo testing is required. 
Moreover, it would be expected that compared to other nanocarriers, 
their selective targeted functionalization will improve the delivery of 
anti-tumoral molecules to specific cell population. 
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